Thermo Fisher – 2023 new APS classification criteria
Thermo Fisher EliA testing for antiphospholipid syndrome (APS) in relation to the new 2023 APS classification criteria.
Thermo Fisher EliA testing for antiphospholipid syndrome (APS) in relation to the new 2023 APS classification criteria.
Phadia 2500+, capacity and productivity that meet the growing demands for laboratories to aid in diagnosing allergic and autoimmune diseases.
Products are for professional/laboratory use only.
Explore the new range of Theradiag IMMUNO-TROL FEIA – a complete range of third-party Quality Controls specifically designed for use with Phadia EliA assays. IMMUNO-TROL FEIA is suitable for use on the Thermo Fisher Phadia range of systems – Phadia 250, Phadia 2500E/EE, Phadia 200.
Products are for professional/laboratory use only.
Antiphospholipid syndrome (APS) is an autoimmune disease which is characterized by the formation of various antibodies against phospholipids and a blood hypercoagulability.
Celiac disease is a chronic and multiorgan autoimmune disease that affects the small bowel in genetically predisposed persons due to the ingestion of gluten1. It can present a wide range of symptoms such as anemia, vague abdominal symptoms, esophagitis, neuropathy, ataxia, depression, short stature, osteomalacia, and multiple others.1 For the majority of patients, their celiac disease remains undiagnosed.1
We would like to share this recent review on the use of tissue transglutaminase antibody titers and use in the diagnosis of celiac disease.
Products are for professional/laboratory use only. ImmunoCAP component from Thermo Fisher – Allergen Component rSes i 1 Sesame seed.
THESE PRODUCTS ARE NOT AVAILABLE FOR PURCHASE BY THE GENERAL PUBLIC.
Phadia Prime is the operator software developed for the Phadia Laboratory Systems: Phadia™ 100, Phadia™ 200, Phadia™ 250, Phadia™ 1000, Phadia™ 2500 series and Phadia™ 5000 series of instrument.
EliA LKM-1 measures antibodies against LKM-1 as an aid in the diagnosis of autoimmune hepatitis type 2 and is the first EliA test for this autoimmune liver disease. It is complementary to the already available EliA M2 that supports the diagnosis of primary biliary cholangitis.